NASDAQ : VTVT
vTv Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 25.17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 312.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 300.06M |
| Enterprise Value | 213.41M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.95M |
| Shares Outstanding | 12.42M |
| Shares Change (YoY) | +74.02% |
| Shares Change (QoQ) | -15.20% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 15.47% |
| Float | 2.16M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.15 |
| Forward PS | n/a |
| PB Ratio | 3.81 |
| P/TBV Ratio | 3.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.48 |
| Quick Ratio | 12.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,541.83 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -15.80% |
| Return on Assets (ROA) | -10.14% |
| Return on Invested Capital (ROIC) | -14.26% |
| Return on Capital Employed (ROCE) | -11.48% |
| Weighted Average Cost of Capital (WACC) | 5.39% |
| Revenue Per Employee | $1.42M |
| Profits Per Employee | -$182,923 |
| Employee Count | 26 |
| Asset Turnover | 0.65 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +11.03% |
| 50-Day Moving Average | 30.10 |
| 200-Day Moving Average | 33.44 |
| Relative Strength Index (RSI) | 29.38 |
| Average Volume (20 Days) | 21,551 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 143,400 |
| Short Previous Month | 156,754 |
| Short % of Shares Out | 1.15% |
| Short % of Float | 6.64% |
| Short Ratio (days to cover) | 3.87 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 36.84M |
| Gross Profit | 8.16M |
| Operating Income | -9.25M |
| Pretax Income | -6.40M |
| Net Income | -4.76M |
| EBITDA | -9.25M |
| EBIT | -9.25M |
| Loss Per Share | -$0.42 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 86.64M |
| Total Debt | n/a |
| Net Cash | 86.64M |
| Net Cash Per Share | $6.97 |
| Equity (Book Value) | 78.63M |
| Book Value Per Share | 6.34 |
| Working Capital | 80.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -16.76M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 6,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -16.76M |
| FCF Per Share | -$1.35 |
Margins
| Measure | Value |
|---|
| Gross Margin | 22.16% |
| Operating Margin | -25.11% |
| Pretax Margin | -17.38% |
| Profit Margin | -12.91% |
| EBITDA Margin | -25.10% |
| EBIT Margin | -25.11% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -74.02% |
| Shareholder Yield | -74.02% |
| Earnings Yield | -1.75% |
| FCF Yield | -5.59% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $56.00 |
| Price Target Difference | 131.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 21, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 18.43 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |